YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Healthcare stocks were lower late Thursday afternoon, with the NYSE Healthcare Index shedding 0.6% a PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
On August 13, ADC Therapeutics (NYSE:ADCT) held its second-quarter earnings call and delivered a mixed message that investors are still sorting through. The company's confirmatory trial for ZYNLONTA in second-line lymphoma cleared its main…
On August 18, ReNew Energy Global (NASDAQ:RNW) reported first-quarter fiscal 2027 results that arrived alongside a much bigger headline than any single quarter usually carries: a binding agreement to take the company private. The operating…
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.5 per share a year ago. These figures are adjusted for non-recurring items.…
Alkermes (ALKS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items. This quar…
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company's main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA's main share of investments to ha…
(RTTNews) - This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology. Regulatory m…
(RTTNews) - ADC Therapeutics SA (ADCT), a commercial-stage biotechnology company, announced it has initiated a strategic reorganisation, including a workforce reduction, to focus resources on key initiatives to advance the ZYNLONTA franchi…
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomla…
(RTTNews) - Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company, announced the appointment of Robert Azelby to its Board of Directors. Azelby brings more than 30 years of experience in executive management, commercial p…
NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomla…
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomla…
[Wall Street New York stock exchange stock market] alexsl Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. M…
Broadcom's (AVGO) decision not to upgrade its 2027 artificial intelligence guidance apparently disap PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
ADC Therapeutics ADCT shares plunged 53.4% in after-hours trading on Wednesday despite the company reporting positive top-line results from a late-stage confirmatory study of Zynlonta in combination with Roche’s RHHBY Rituxan (rituximab) f…
[Wall Street New York City] aluxum/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-down moves before the bell Thursday. Stock index futures (SPX [https://seekingalpha.com/symbol/SPX]) were mixed before the bell on…
ADC Therapeutics S.A. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Market Positioning Management attributes the 15% year-over-year revenue growth primarily to normal customer ordering variability rather than a fundamental…
Earnings Call Insights: ADC Therapeutics (ADCT) Q1 2026 MANAGEMENT VIEW * "We continue to make good progress in the first quarter of 2026 as we advance towards multiple important milestones for ZYNLONTA over the remainder of the year, begi…
ADC Therapeutics logo Key Points ADC reported Q1 2026 net product revenue for ZYNLONTA of $20.0 million (up from $17.4M a year ago), which management said mainly reflects quarter-to-quarter ordering variability with underlying demand broad…
Major earnings expected before the bell on Monday include: * Norwegian Cruise Line Holdings Ltd. (NCLH [https://seekingalpha.com/symbol/NCLH]) * Tyson Foods (TSN [https://seekingalpha.com/symbol/TSN]) * Axsome Therapeutics (AXSM [https://s…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. ADC Therapeutics SA (ADCT) is a stock that can certainly grab the attention of many investors, but do its recent returns co…
ADC Therapeutics (NYSE:ADCT) is one of the best growth stocks to buy right now. On March 10, ADC Therapeutics reported its financial and operational results for Q4 and the full-year 2025, highlighting upcoming clinical milestones for its l…
ADC Therapeutics logo Key Points ADC has refocused on ZYNLONTA with an optimized lifecycle plan and ~50% reduction in operating costs, while bolstering the balance sheet via $100M and $60M PIPE financings to support a cash runway into at l…
(RTTNews) - ADC Therapeutics SA (ADCT) reported a net loss for the quarter ended December 31, 2025, of $6.4 million, or a net loss of $0.04 per share, as compared to net loss of $30.7 million, or a net loss of $0.29 per share, prior year.…
* ADC Therapeutics press release [https://seekingalpha.com/pr/20430415-adc-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides] (ADCT [https://seekingalpha.com/symbol/ADCT]): Q4 Non-GAAP EPS of -$0.05. * R…
Major earnings expected after the bell on Tuesday include: * NIO (NIO [https://seekingalpha.com/symbol/NIO]) * BioNTech SE (BNTX [https://seekingalpha.com/symbol/BNTX]) * Uranium Energy Corp. (UEC [https://seekingalpha.com/symbol/UEC]) * K…
The following companies are expected to report earnings prior to market open on 03/10/2026. Visit our Earnings Calendar for a full list of expected earnings releases. BioNTech SE (BNTX)is reporting for the quarter ending December 31, 2025.…
* ADC Therapeutics (ADCT [https://seekingalpha.com/symbol/ADCT]) is scheduled to announce Q4 earnings results on Tuesday, March 10th, before market open. The consensus EPS Estimate is -$0.27 [https://seekingalpha.com/symbol/ADCT/earnings/e…
[Young female scientist working in laboratory] Solskin Pharmaceutical (PJP [https://seekingalpha.com/symbol/PJP]), (XPH [https://seekingalpha.com/symbol/XPH]), (PPH [https://seekingalpha.com/symbol/PPH]) and biotechnology stocks (XBI [http…
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at ne…
* ADC Therapeutics SA (ADCT [https://seekingalpha.com/symbol/ADCT]) said on Thursday it expects preliminary unaudited net product revenue of about $22 million for the fourth quarter of 2025 and approximately $73 million for the full year.…
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC Therapeutics” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at ne…
Catalyst Funds chief investment officer and senior portfolio manager David Miller and Marketgauge.com chief strategist Michele Schneider join Morning Brief host Julie Hyman to share some of their top stock picks in the healthcare (XLV) sec…
ADC Therapeutics (NYSE:ADCT) is one of the best multibagger penny stocks to buy right now. On December 4, Guggenheim analyst Michael Schmidt reaffirmed his Buy rating on ADC Therapeutics (NYSE:ADCT) and set a price target of $10.00. On Dec…
(RTTNews) - ADC Therapeutics. (ADCT) is scheduled to host a conference call today at 8:00 a.m. EST to provide an update on its LOTIS-7 trial. LOTIS-7 is a Phase 1b open-label clinical trial evaluating the safety and efficacy of the company…
* ADC Therapeutics press release [https://seekingalpha.com/pr/20300217-adc-therapeutics-reports-third-quarter-2025-financial-results-and-provides-operational-update] (ADCT [https://seekingalpha.com/symbol/ADCT]): Q3 Non-GAAP EPS of -$0.19.…